Literature DB >> 9529615

Blood pressure control, proteinuria and renal outcome in chronic renal failure.

L M Ruilope, C Campo, J L Rodicio.   

Abstract

The presence of proteinuria has been shown to be an excellent predictor for a worse outcome of renal function. Both proteinuria and arterial hypertension often coexist in the same patient, and therapy must be directed at decreasing protein excretion in the urine as well as lowering the blood pressure. Any antihypertensive agent has the capacity to lower proteinuria simply by lowering blood pressure. Furthermore, the antiproteinuric capacity of angiotensin-converting enzyme inhibitors can be equalized by other agents or their combination, provided that the fall in blood pressure is great enough. For this reason studies are needed in which the strict control of arterial hypertension combined with a decrease in proteinuria are considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529615     DOI: 10.1097/00041552-199803000-00001

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  4 in total

Review 1.  The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?

Authors:  L M Ruilope; C Campo; J Segura
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 2.  Lessons from trials in hypertensive type 2 diabetic patients.

Authors:  Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 3.  How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?

Authors:  Julian Segura; Helle Christiansen; Carlos Campo; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

Review 4.  Renal protection by antihypertensive therapy.

Authors:  Luis M Ruilope; Julian Segura
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.